12th Biosimilars Congregation 2018 Business

provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

12th Biosimilars Congregation 2018
“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”
27th & 28th February 2018, Holiday Inn, Kensington High Street, London, UK
12th Biosimilars Congregation 2018 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies, our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines.
KEY SPEAKERS:
• NIRAJ CHHAYA, Senior Risk Management Physician of Biosimilar Compounds, Boehringer Ingelheim
• THOMAS SACHNIK, Senior Manager Strategic Associate to the President & CEO Generics Europe, Teva Pharmaceuticals
• SUE NAEYAERT, Global Head Pricing, Market Access, Government Affairs and Policy Biosimilars, Fresenius Kabi SwissBioSim
• CHRISTIAN AGBOTON, Sr Global Brand Medical Director - Global Medical Affairs, Takeda
• KAUSTUBH BERDE, Vice President - International Business : Emerging Markets, Wockhardt
• CORNELIA ULM, VP Regulatory Affairs Biosimilars, Biotec Regulatory Consulting GmbH (former Fresenius Kabi SwissBioSim GmbH)
• HANMANT BARKATE, Vice President & Head Medical Services, Glenmark
• ANNA AILLERIE, Director, Commercial Biosimilars EMEA, Lupin
• LIZ POLLITT, Director, BPCRCS
• FREDRIK SUNDBERG, Director Strategic Customer Relations, GE Healthcare
• BER OOMEN, Expert Member Health Care Professionals, European Medicines Agency
• MAARTEN VAN BAELEN, Market Access Director, Medicines for Europe
• LOUIS BOON, CSO, Bioceros
• PETER JORGENSEN, CEO, Danish Generic and Biosimilar Medicines Industry Association (IGL)
• ANDREAS HERRMANN, CEO, ValeriusBio
• VLADIMIR ZAH, CEO, ZRx Outcomes Research (Canada)
• ROBERT A. JOHNSTONE, Board Member, International Alliance of Patients Organisations
• STEINAR MADSEN, Medical Director, Norwegian Medicines Agency
• OMAR ALI, Visiting Lecturer, University of Portsmouth & Former Adviser, NICE
• FEDERICO POLLANO, Director Contract Manufacturing and BD, Polpharma Biologics
• ALEX KUDRIN, Independent Consultant and clinical expert
• DIVYA CHADHA MANEK, Head of BD (Commercial), NHS - NIHR Clinical Research Network
• PAUL CALVO, Director, Sterne, Kessler, Goldstein & Fox (USA)
• AIDAN FRY, Editor, Generics Bulletin
• SANDY EISEN, Chief Medical Officer, Frontline Pharma Consulting
• ANNA FORSYTHE, Managing Partner, Purple Squirrel Economics (USA)
• MARIE MANLEY, Partner, Head of the Regulatory Practice, Bristows
• JACQUELINE MULRYNE, Counsel, Arnold & Porter
WHO SHOULD ATTEND:
CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:
Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs , Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing.
CONFERENCE BOOKING DETAILS:-
You can simply share your interest and queries to –Email: [email protected] TEL: +44 2036120886
• Introductory Offer: 3 Delegate Places for the Price Of 2 (Huge saving of £750 - Limited seats left)
• Super Early Discount (Until 17th December 2017): (£750 + VAT per delegate)
• Standard Registration (From 18th December 2017):: Conference Delegate Pass (£1150 + VAT per delegate
• Conference Sponsor, Exhibition Stalls & a paid Speaker Slots are also available.

Join this event which provides an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

More details